NEWS TODAY
(COMTEX) B: Analex's Advanced Biosystems Subsidiary Awarded New $3 Milli
B: Analex's Advanced Biosystems Subsidiary Awarded New $3 Million Biodefense
Contract by DARPA
ALEXANDRIA, Va., Aug 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Analex
Corporation (OTC Bulletin Board: ANLX) today announced that its Advanced
Biosystems, Inc. subsidiary has been awarded a new $3 million contract by the
Defense Advanced Research Projects Agency (DARPA). This eight-month contract
builds upon medical biodefense research findings previously funded by DARPA, and
initiates studies to develop immune system research models. Other members of
Advanced Biosystems' team include George Mason University, Sciperio, Inc.,
Southern Research Institute, and Structural Bioinformatics, Inc.
The research is being conducted under the direction of Advanced Biosystems' Vice
Chairman and Chief Scientist, Dr. Ken Alibek, who has vast experience in the
development of these and other novel methods of prophylaxis (prevention) and
treatment of a broad spectrum of infectious diseases. This new biodefense
contract focuses on researching ways to enhance the body's innate immune
response against a wide variety of biological weapons threats. The areas under
investigation will include an expansion of prior in vitro and in vivo studies of
the effects of certain cytokines and other modulators of the innate immune
response; the computer modeling, design, construction, and in vitro testing of a
new peptide designed to mimic the immunomodulating effects of a specific
cytokine; and initial studies of various tissue deposition techniques to be used
in creating a three-dimensional model of mucosal immunity.
"We are gratified that our prior research has yielded promising results, and we
are pleased to continue working with DARPA to develop advanced protection
against biological threat agents," Dr. Alibek stated. "Under this contract we
will also continue the development, and small animal in vivo testing, of
prototype biodefense products. Our Company continues to explore opportunities to
license its developing technology to, or seek a joint venture with, a partner to
complete the necessary clinical trials, regulatory approvals, and the
development, manufacturing, and marketing of any future products that might
arise from this work," he added.
Analex's President and Chief Executive Officer, Sterling Phillips, commented,
"We are pleased with the continuing recognition of Advanced Biosystems' efforts
to develop protection against biological agents that may be used in warfare or
terrorist attacks. This research is an important component of Analex's
commitment to supporting national security."
Analex specializes in developing intelligence, systems engineering and
biodefense solutions in support of our nation's security. Analex focuses on
designing, developing and testing aerospace products and systems; developing
innovative technical solutions for the intelligence community, analyzing and
supporting defense systems; and developing medical defenses and treatments for
infectious agents used in biological warfare and terrorism. The Company's stock
trades on the OTC Electronic Bulletin Board under the symbol ANLX. The Company
can be found on the Internet at analex.com . Analex investor
relations can be contacted at (703) 329-9400 or via email at agordon@hadron.com.
PLEASE NOTE: Except for the historical information contained herein, this press
release contains forward-looking statements within the meaning of Section 21E of
the Securities and Exchange Act of 1934, as amended, that involve a number of
risks and uncertainties. These forward-looking statements may be identified by
reference to a future period by use of forward-looking terminology such as
"anticipate," "expect," "could," "intend," "may" and other words of similar
nature. There are certain important factors and risks that could cause results
to differ materially from those anticipated by the statements contained herein.
Such factors and risks include business conditions and growth in the medical
research, pharmaceutical and government contracting arenas and in the economy in
general. Competitive factors include the pressures toward consolidation of small
government contracts into larger contracts awarded to major, multi-national
corporations; and the Company's ability to continue to recruit and retain highly
skilled scientific, technical, managerial and sales/marketing personnel. Other
risks may be detailed from time to time in the Company's filings with the
Securities and Exchange Commission. Analex undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE Analex Corporation
CONTACT: Amber Gordon or Sterling Phillips, both of Analex Corporation
+1-703-329-9400
URL: analex.com
prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
-0-
KEYWORD: Virginia
INDUSTRY KEYWORD: ARO
CPR
BIO
SUBJECT CODE: CON
*** end of story ***
View Next 10 Messages | Previous | Next
Remove Bookmark Ignore this Person Report a TOU violation View SubjectMarks
Enter symbols or keywords for search:
QuotesStock TalkChartsNewsPeople Symbol Lookup
Subject Titles Only Full Text This Subject Only Go to Top
Terms of Use
Got a comment, question or suggestion? Contact Silicon Investor. |
